Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging
Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022.
https://finance.yahoo.com/news/mymd-pharmaceuticals-receives-fda-ind-142500188.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.